SeraCare expands genetic portfolio, 6/14
June 2014—SeraCare launched its Accurun 611 product, a reference material that provides heterozygous, mutant, or wild-type scores for Factor II, Factor V, and Methlyenetetrahydrofolate reductase.
Webinars and Sponsored Roundtables — Register Now
Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Tosoh Bioscience Inc.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from OncoLens and Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The roundtable is made possible by a special educational grant from Pillar Biosciences.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Illumina.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
POC devices, 6/14
June 2014—The Minivette POC testing devices from Sarstedt are for the collection, transfer, and subsequent dispensing of small capillary blood samples for point-of-care tests. Blood is collected via capillary action into the collection capillary, the sample is held securely during transfer, and then it is dispensed onto the test field or into a micro tube with a slight push of the opposing integral piston.
Enterovirus monoclonal antibodies, 6/14
June 2014—ViroStat released a pan-reactive monoclonal antibody that is positive for all 27 enteroviruses tested to date.
Next-generation blood gas analyzer, 6/14
May 2014—The Stat Profile Prime is a blood gas analyzer from Nova Biomedical. It combines the company’s MicroSensor Card with its Zero maintenance cartridge technology, which consists of individual cartridges for biosensors, calibrators, and liquid quality control.
New antibodies and antigens, 6/14
June 2014—The Binding Site has expanded its offering of clinical and research products to include a distinctive group of horseradish peroxidase conjugated sheep antibodies specific to human IgA, IgG, and IgM immunoglobulins and their fractional components.
Reusable sharps container, 5/14
December 2013—Rehrig Pacific’s SharpsTank reusable sharps container model TS has received FDA 510(k) clearance as a class II medical device. The SharpsTank model TS is a 4.9-gallon reusable container with an integrated hinged lid, restrictive mail chute, and flusher insert. The container is supplied to the customer fully assembled.
Clarient adopts THxID-BRAF, 5/14
April 2014—BioMérieux’s molecular diagnostic test THxID-BRAF has been added to the offerings provided by Clarient, a GE Healthcare company.
ConfirmMDx case study, 5/14
May 2014—Cancer test was used as part of a multidisciplinary approach to confirm prostate cancer diagnosis using a technique called transperineal mapping biopsy. The cancer lesions found using this method were not detected by five conventional biopsies.
Multilabel slide scanner, 5/14
May 2014—PerkinElmer launched the Lamina multilabel slide scanner at the USCAP 2014 Annual Meeting. The scanner is a high-throughput imaging system for research pathologists in a larger research facility to study protein expression and the relationships between disease markers in formalin-fixed, paraffin-embedded tissue sections.
Insight Genetics and VICC partnership, 5/14
May 2014—Insight Genetics is collaborating with Vanderbilt-Ingram Cancer Center (VICC) to identify genetic markers that will help select the targeted therapeutics most effective for each triple-negative breast cancer patient.